IMV to Announce Fourth Quarter & Full Year 2019 Financial & Operational Results & Host Investor Conference Call & Webcast on ...
25 March 2020 - 10:05PM
Business Wire
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a
clinical-stage biopharmaceutical company pioneering a novel class
of immunotherapies, announced today that it will hold a conference
call and webcast on Wednesday, March 31, 2020 at 8:00 a.m. Eastern
Time to discuss the company’s 2019 fourth quarter and full year
financial and operational results.
Financial analysts are invited to join the conference call by
dialing (866) 211-3204 (U.S. and Canada) or (647) 689-6600
(international) using the conference ID: 7482187.
Other interested parties will be able to access the live audio
webcast at this link:
https://ir.imv-inc.com/events-and-presentations. The webcast will
be recorded and will then be available on the IMV website for 30
days following the call.
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated
to making immunotherapy more effective, more broadly applicable,
and more widely available to people facing cancer and other serious
diseases. IMV is pioneering a new class of immunotherapies based on
the Company’s proprietary drug delivery platform. This patented
technology leverages a novel mechanism of action that enables the
programming of immune cells in vivo, which are aimed at generating
powerful new synthetic therapeutic capabilities. IMV’s lead
candidate, DPX-Survivac, is a T cell-activating immunotherapy that
combines the utility of the platform with a target: survivin. IMV
is currently assessing DPX-Survivac in advanced ovarian cancer, as
well as in a combination therapy in multiple clinical studies with
Merck’s Keytruda®. Connect at www.imv-inc.com.
IMV Forward-Looking Statements
This press release contains forward-looking information under
applicable securities law. All information that addresses
activities or developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. In the press release, such forward-looking
statements include, but are not limited to, statements regarding
the FDA potentially granting accelerated regulatory approval of
DPX-Survivac and the timing of expected results from other
DPX-Survivac’s studies with other tumor types. However, they should
not be regarded as a representation that any of the plans will be
achieved. Actual results may differ materially from those set forth
in this press release due to risks affecting the Corporation,
including access to capital, the successful design and completion
of clinical trials and the receipt and timely receipt of all
regulatory approvals. IMV Inc. assumes no responsibility to update
forward-looking statements in this press release except as required
by law. These forward-looking statements involve known and unknown
risks and uncertainties and those risks and uncertainties include,
but are not limited to, our ability to access capital, the
successful and timely completion of clinical trials and studies,
the receipt of all regulatory approvals and other risks detailed
from time to time in our ongoing quarterly filings and annual
information form Investors are cautioned not to rely on these
forward-looking statements and are encouraged to read IMV’s
continuous disclosure documents, including its current annual
information form, as well as its audited annual consolidated
financial statements which are available on SEDAR at www.sedar.com
and on EDGAR at www.sec.gov/edgar.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200325005056/en/
Investor Relations Marc Jasmin, Senior Director,
Investor Relations, IMV O: (902) 492-1819, ext: 1042 M: (514)
617-9481 E: mjasmin@imv-inc.com
Josh Rappaport, Director, Stern IR O: (212) 362-1200 E:
josh.rappaport@sternir.com
Media Mrs. Delphine Davan, Director of Communications,
IMV M: (514) 968-1046 E: ddavan@imv-inc.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024